ARO-C3

RNA / oligonucleotide

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Complement-Mediated Renal Disease

Competitive landscape

3 other tracked programmes target this mechanism, 3 of them ahead of this one.

This drug's own stage for Complement-Mediated Renal Disease: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
ARO-C3: this drugPhase 1/2RNA / oligonucleotideComplement C3not yet gradedNo reviewed efficacy summary in this indication
Iptacopan (Fabhalta)ApprovedSmall moleculeComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication
Pegcetacoplan (Empaveli)ApprovedPeptideComplement C3not yet gradedNo reviewed efficacy summary in this indication
Pegcetacoplan Ophthalmic (Syfovre)
Approved(overall)
PeptideComplement C3, Complement C3 / C3b
Reliable signal(overall)
No reviewed efficacy summary in this indication
Cevolisiran
Phase 2(overall)
RNA / oligonucleotideComplement C3
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

10 March 2025Topline resultARO-C3 Phase 1/2 Part 2 topline results in IgA nephropathy
Arrowhead Pharmaceuticals · Source ↗